UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2016
AIMMUNE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-37519 |
|
45-2748244 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
8000 Marina Blvd, Suite 300
Brisbane, CA 94005
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 614-5220
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
2016 Annual Salaries and 2015 Fiscal Year Cash Bonuses
On February 19, 2016, the Compensation Committee (the “Committee”) of Board of Directors (the “Board”) of Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) , approved the 2016 annual salaries (retroactive to January 1, 2016), 2015 cash bonuses and stock option awards for the Company’s Chief Financial Officer and Chief Medical Officer. In addition, on February 22, 2016, the Board approved, on recommendation of the Committee, the 2016 annual salary (retroactive to January 1, 2016), 2015 cash bonus and stock option award to the Company’s Chief Executive Officer. The stock option awards to each of the executive officers will be granted effective as of the close of business on February 26, 2016 with an exercise price equal to the closing price of the Company’s common stock as reported on The NASDAQ Global Select Market on the date of grant. The awards will be made pursuant to the Company’s 2015 Equity Incentive Award Plan and will vest in equal monthly installments over 48 months, subject to continued service as of each vesting date.
The following table sets forth the 2016 annual salaries, 2015 cash bonus and number of shares underlying the stock option awards for each of the named executive officers and principal financial officer:
Name and Principal Position
|
2016 Salary ($)
|
2015 Cash Bonus ($)
|
Stock Option Award (shares)
|
Dr. Stephen G. Dilly……………………………….. |
$440,000 |
$192,000 |
240,000 |
Chief Executive Officer |
|
|
|
Warren L. DeSouza. |
$332,000 |
$76,500 (1) |
80,000 |
Chief Financial Officer |
|
|
|
Dr. Robert Elfont |
$370,050 |
$119,300 |
80,000 |
Chief Medical Officer |
|
|
|
______________
(1) 2015 cash bonus is prorated reflecting service to the Company for approximately 70% of the 2015 fiscal year.
Aimmune Therapeutics, Inc. Company Bonus Plan
On February 19, 2016, the Committee approved the Aimmune Therapeutics, Inc. Company Bonus Plan for executive officers and eligible employees of the Company and its subsidiaries (the “Bonus Plan”). The Bonus Plan is a discretionary cash incentive award plan designed to align incentive awards for each participant’s individual performance with the Company’s annual corporate performance objective. Eligibility to participate in the plan and actual award amounts are not guaranteed and are determined at the discretion of the Committee. The bonus that can be earned by any eligible employee during any annual performance period is based upon such employee’s target bonus percentage, which is expressed as a percentage of such employee’s base salary and shall be established from time to time by the Committee. Actual awards under the Bonus Plan for each exempt eligible employee, including executive officers, may exceed or be less than the target bonus percentage for such employee depending upon the Company’s attainment of corporate performance objectives and/or individual performance objectives, which shall be established for each annual performance period by the Committee (the “Performance Goals”). For each performance Period, the Committee may determine a “threshold,” “target” and “stretch” level of attainment for each Performance Goal, with the applicable percentage achievement corresponding to each level of attainment, including any intermediate levels of attainment and the weighting of each Performance Goal. Unless determined otherwise by the Committee, in its sole discretion, the maximum amount payable to any eligible employee shall be two hundred percent (200%) of such employee’s target bonus percentage in any given annual performance period. The Committee shall administer the Plan and awards to “covered employees” within the meaning of Section 162(m) of the Internal Revenue Code of 1986, as amended, shall be under the Company’s 2015 Equity Incentive Award Plan and thus subject to its terms and conditions.
The foregoing description of the material terms of the Bonus Plan is qualified in its entirety by the complete terms of the Bonus Plan, which is filed as Exhibit 10.1 to this Current Report.
Item 9.01 Financial Statements and Exhibits.
Reference is made to the Exhibit Index attached hereto.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AIMMUNE THERAPEUTICS, INC. |
Date: February 25, 2016 |
By: /s/ Warren L. DeSouza Warren L. DeSouza Chief Financial Officer and Corporate Secretary |
EXHIBIT INDEX
Exhibit No. |
|
Description |
10.1 |
|
Aimmune Therapeutics, Inc. Corporate Bonus Plan. |
Exhibit 10.1
Aimmune Therapeutics, Inc.
Company Bonus Plan
1. |
Purpose |
This Aimmune Therapeutics, Inc. Company Bonus Plan (the “ Plan ”) is intended to provide an incentive for achievement of annual corporate goals and to motivate eligible executives and employees of Aimmune Therapeutics, Inc. (the “ Company ”) and its subsidiaries toward high achievement and solid business results, to tie their goals and interests to those of the Company and its stockholders and to enable the Company to attract and retain employees. The Plan is for the benefit of Eligible Employees (as defined below) and shall be implemented in consecutive annual performance periods (each, a “ Performance Period ”) commencing on January 1, 2016 (the “ Effective Date ”).
2. |
Eligible Employees |
(a) The Compensation Committee of the Board of Directors of the Company (the “ Administrator ”) shall determine which employees of the Company and its subsidiaries shall be eligible to participate in the Plan for a given Performance Period (the “ Eligible Employees ”). Participation in the Plan is in the sole discretion of the Administrator. Accordingly, an Eligible Employee who is a participant in the Plan is in no way is guaranteed or assured of being selected for participation in any subsequent Performance Period.
(b) Notwithstanding anything herein to the contrary, with respect to Eligible Employees who are “covered employees” within the meaning of Section 162(m) of the Internal Revenue Code of 1986, as amended (the “ Code ”), bonuses awarded hereunder shall be under the Company’s 2015 Equity Incentive Award Plan and thus subject to its terms and conditions.
3. |
Administration |
The Administrator shall have the sole discretion and authority to administer and interpret the Plan.
4. |
Bonus Determinations |
(a) The bonus pool for each Performance Period shall be funded based upon Company attainment of corporate performance objectives which are established for the Performance Period by the Administrator (the “ Performance Goals ”). The Administrator shall determine a “threshold,” “target” and “stretch” level of attainment for each Performance Goal, the applicable percentage achievement corresponding to each level of attainment, including any intermediate levels of attainment (the “ Achievement Level Factor ”) and the weighting of each Performance Goal.
(b) The amount of bonus that can be earned by any Eligible Employee during the Performance Period shall be based on the Eligible Employee’s target bonus percentage (“ Target Bonus Percentage ”), which shall be established by the Administrator and expressed as a percentage of the Eligible Employee’s base salary. Except as required by applicable law, overtime and double time wages for non-exempt Eligible Employees are excluded from base
s alary. Unless determined otherwise by the Administrator, in its sole discretion, the maximum amount payable to any Eligible Employee shall be two hundred percent (200%) of such Eligible Employee’s Target Bonus Percentage in any given Performance Period.
(c) Each exempt employee’s bonus will be determined based on the Company’s achievement of the Performance Goals and their individual performance, which shall be weighted as determined by the Administrator in its sole discretion (the “ Performance Mix ”). Bonus awards for eligible non-exempt employees shall not be based upon achievement of Performance Goals, but shall be determined by his or her manager’s assessment of the eligible non-exempt employee’s individual performance and contributions relative to others in their organization, as determined in the sole and absolute discretion of the manager.
(d) As soon as administratively practicable following the date financial statements for the Performance Period are finalized and available from the Company, the Administrator shall determine the achievement level of each Performance Goal for the full Performance Period. The corporate performance component for each exempt Eligible Employee (the “ Corporate Component ” ) shall be the sum of the amount for each Performance Goal calculated by multiplying (1) the Achievement Level Factor for the applicable Performance Goal times (2) the weighting for such Performance Goal times (3) the Target Bonus Percentage for the exempt Eligible Employee times (4) the exempt Eligible Employee’s annual base salary and (5) any proration applied based on an employee’s new hire date or any other change in position, as determined by the Administrator.
(e) An exempt Eligible Employee’s actual bonus payment (“ Bonus Payment ”) for a given Performance Period will be weighted according to the exempt Eligible Employee’s Performance Mix and calculated based on the Corporate Component , as well as an individual component (the “ Individual Component ”) determined by the exempt Eligible Employee’s manager through consideration of such exempt Eligible Employee’s individual performance and contribution during the Performance Period relative to others in their organization. The Administrator will also have the ability to consider such Eligible Employee’s performance and contribution relative to all Company employees at the same level in determining an individual’s actual final Bonus Payment. Unless otherwise determined by the Administrator, Eligible Employees who are on a Performance Improvement Plan at the time bonuses are determined hereunder shall have any applicable Individual Component deemed achieved at 0%.
(f) Subject to Section 2(b) hereof, the Administrator may, in its sole discretion and at any time, (i) pay bonuses (including, without limitation, discretionary bonuses) to Eligible Employees under the Plan based upon such other terms and conditions as the Administrator may in its discretion determine, (ii) increase, reduce or eliminate any bonus otherwise payable under the Plan and/or (iii) establish or modify Performance Periods. The Administrator may determine the amount of any reduction on the basis of such factors as it deems relevant, and shall not be required to establish any allocation or weighting with respect to the factors it considers.
(g) The payment of a bonus to an Eligible Employee with respect to the Performance Period shall be conditioned upon the Eligible Employee’s employment by the Company on the date such payment is made; provided, however , that the Administrator may make exceptions to this requirement, in its sole discretion, including, without limitation, in the case of an Eligible Employee’s termination of employment, retirement, death or disability. Payment of bonuses to Eligible Employees shall be made as soon as practicable, as determined by the Administrator after the end of the Performance Period.
2
(h) Employees not on Aimmune’s payroll on or before September 30 of the Plan year will not be bonus eligible in that Plan year.
5. |
Amendment and Termination |
The Company reserves the right to amend or terminate the Plan at any time in its sole discretion.
6. |
Tax Withholding |
The Company shall withhold all applicable taxes from any bonus payment made under the Plan, including any federal, state and local or foreign taxes (including, but not limited to, FICA and SDI obligations).
7. |
No Effect on Employment or Service |
Nothing in the Plan shall interfere with or limit in any way the right of the Company or any of its affiliates to terminate any Eligible Employee’s employment or service at any time, with or without cause. Except as may otherwise be provided by applicable law or a binding written agreement entered into between the Company and any Eligible Employee, an Eligible Employee’s employment with the Company and its affiliates is on an at-will basis only. The Company expressly reserves the right, which may be exercised at any time and without regard to when during a performance period such exercise occurs, to terminate any individual’s employment with or without cause, and to treat him or her without regard to the effect that such treatment might have upon him or her as an Eligible Employee.
8. |
Term of Plan |
The Plan shall become effective as of the Effective Date, and it shall remain in effect until all payments with respect to the Performance Period have been made.
9. |
Unfunded Obligations |
The rights of Eligible Employees under the Plan shall be unfunded and unsecured. Amounts payable under the Plan are not and will not be transferred into a trust or otherwise set aside. Neither the Company nor any subsidiary shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any bonus under the Plan.
10. |
Rights Not Transferable |
No rights of any Eligible Employee to payments of any amounts under the Plan shall be sold, exchanged, transferred, assigned, pledged, hypothecated or otherwise disposed of other than by will or by laws of descent and distribution, and any such purported sale, exchange, transfer, assignment, pledge, hypothecation or disposition shall be void.
11. |
Governing Law |
3
The Plan and the rights and obligations of the parties to the Plan shall be governed by, and construed and interpreted in accordance with, the law of the State of California (without regard to principles of conflicts of law).
12. |
Section 409A |
It is intended that the payments under this Plan comply with or be exempt from Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder (“ Section 409A ”), including without limitation any such regulations or other guidance that may be issued after the Effective Date. Accordingly, to the maximum extent permitted, this Plan shall be interpreted to be in compliance with Section 409A and any payment hereunder shall be made in compliance with or pursuant to an exemption from Section 409A.
4